-+ 0.00%
-+ 0.00%
-+ 0.00%

Nuvectis Pharma Launches Phase 1b Trial of NXP900 and Osimertinib in EGFRmut+ NSCLC

Reuters·12/17/2025 12:00:25

Please log in to view news